Brain cancer survivor Mike Schuster celebrates a milestone he never thought possible.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Doctors exhausted conventional treatments for Mike Schuster. Can an experimental OMRF drug stop his brain cancer? *** In the summer of 2010, Mike and Teresa Schuster took their two boys to Mexico’s Yucatan Peninsula. The Schusters live in Norman, where Teresa is an administrative assistant in the University of Oklahoma’s Office of Student Affairs and […]